SLC33A1抗体;SLC33A1 Antibody—艾普蒂

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: Mouse liver tissue, Primary antibody: P11352(SLC33A1 Antibody) at dilution 1/1100, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

The SLC33A1 antibody targets the solute carrier family 33 member 1 (SLC33A1), a transmembrane protein critical for acetyl-CoA transport into the Golgi lumen. This protein, also known as AT-1. plays a key role in post-translational acetylation processes, including the acetylation of gangliosides, glycoproteins, and histones. Dysregulation of SLC33A1 has been implicated in neurodegenerative disorders such as Alzheimer’s disease, Huntington’s disease, and autism spectrum disorders, as well as in metabolic conditions like diabetes.

SLC33A1 antibodies are widely used in research to study the protein’s expression, localization, and function in cellular models and tissues. These antibodies are typically produced in host species like rabbits or mice using immunogenic peptides or recombinant protein fragments. They enable detection via techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF).

Recent studies highlight SLC33A1’s involvement in autophagy and copper homeostasis, with mutations linked to rare genetic disorders like Huppke-Brendel syndrome. Researchers also explore its role in cancer progression, as altered acetyl-CoA metabolism may influence tumor growth. Validation of SLC33A1 antibodies includes specificity checks using knockout controls and functional assays to confirm physiological relevance. Understanding SLC33A1’s mechanisms could uncover therapeutic targets for diseases associated with acetyl-CoA dysregulation.